Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Total Debt (2020 - 2023)

C4 Therapeutics has reported Total Debt over the past 4 years, most recently at $10.3 million for Q2 2023.

  • For Q2 2023, Total Debt fell 7.08% year-over-year to $10.3 million; the TTM value through Jun 2023 reached $10.3 million, down 7.08%, while the annual FY2022 figure was $11.5 million, 6.63% up from the prior year.
  • Total Debt for Q2 2023 was $10.3 million at C4 Therapeutics, down from $10.9 million in the prior quarter.
  • Over five years, Total Debt peaked at $11.5 million in Q4 2022 and troughed at $9.9 million in Q3 2020.
  • A 4-year average of $10.7 million and a median of $10.7 million in 2021 define the central range for Total Debt.
  • Biggest five-year swings in Total Debt: grew 7.2% in 2021 and later fell 7.08% in 2023.
  • Year by year, Total Debt stood at $10.1 million in 2020, then rose by 7.12% to $10.8 million in 2021, then increased by 6.63% to $11.5 million in 2022, then fell by 9.99% to $10.3 million in 2023.
  • Business Quant data shows Total Debt for CCCC at $10.3 million in Q2 2023, $10.9 million in Q1 2023, and $11.5 million in Q4 2022.